Contingent Value Rights (CVR)
A Contingent Value Right (CVR) is a contractual right, issued to shareholders of a company being acquired, that entitles them to an additional cash or stock payment if a specified future event actually happens - commonly a drug winning regulatory approval, a legal case being resolved favorably, or a business unit hitting a revenue target. A CVR is not a share of stock and does not carry ownership rights like voting or dividends; it is purely a conditional promise to pay, and many CVRs are listed and can be bought or sold separately from the underlying deal.
CVRs typically appear when a buyer and seller disagree about how to value an uncertain future outcome. For example, in a $50-per-share buyout of a biotech company, the acquirer might offer shareholders $45 per share in cash upfront plus a CVR worth up to $5 per share, payable only if a drug in the company's pipeline receives FDA approval within three years - letting the deal close now while splitting the risk of that pending decision. Practically, CVRs matter to stocks investors evaluating a merger offer because the "extra" value is never guaranteed: CVRs often trade at a steep discount to their maximum stated payout, reflecting the market's own estimate of how likely the milestone is to be hit, and many expire completely worthless if the condition is never satisfied.
The record of these things is not encouraging, and it is worth knowing the pattern before treating one as part of the price. Milestones are written to be demanding, because the buyer is agreeing to pay extra only for an outcome it doubts; deadlines are fixed and drug development slips; and a great many rights simply expire. Where they do pay, the amount is often less than the headline, because the terms are staged - so much for approval in one market, so much more for a sales threshold that is never reached.
The other recurring problem is that the buyer ends up controlling whether the milestone happens. Once the acquisition closes, it is the acquirer who decides how hard to push a trial, how much to spend on a launch, and which markets to file in - and holders of the right have no vote and no board seat. Deal documents try to handle this with a promise to use commercially reasonable efforts, a phrase vague enough that disputes over it have repeatedly ended up in court. Anyone valuing one of these should therefore start from the traded price rather than the maximum: the market is already pricing the odds, and where the right is not listed at all, the honest assumption is that the cash portion is the offer and the rest is a lottery ticket.